Without Roche, Epigenomics Completes Validation Study for Prostate Cancer Dx | GenomeWeb

NEW YORK, Jan. 4 (GenomeWeb News) - Epigenomics will develop a DNA methylation test for prostate cancer on its own after erstwhile partner Roche Diagnostics decided to back out of their alliance, the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.